ASAN FOUNDATION
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Study of Laparoendoscopic Single Site Adnexal Surgery for Benign Ovarian and Tubal Disease
Not Applicable
- Conditions
- Benign Ovarian or Tubal Disease
- Interventions
- Procedure: Three-port laparoscopic adnexal surgeryProcedure: Single-port laparoscopic adnexal surgery
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 330
- Registration Number
- NCT01679509
- Locations
- 🇰🇷
Department of Obstetrics and Gynecology, Universit of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
Not Applicable
Completed
- Conditions
- Ovarian CancerFallopian Tubal CancerGynecologic CancerEndometrial CancerCervical Cancer
- Interventions
- Drug: FloSeal application
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01679483
- Locations
- 🇰🇷
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Phase 2
Completed
- Conditions
- Rectal CancerLiver Metastases
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT01643070
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of
Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Chronic Viral Hepatitis B Without Delta-agent
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 102
- Registration Number
- NCT01639066
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Chronic Viral Hepatitis B Without Delta-agent
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 88
- Registration Number
- NCT01639092
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
Phase 3
- Conditions
- Breast Cancer
- Interventions
- Drug: Adriamycin+Cyclophosphamide>Docetaxel
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 290
- Registration Number
- NCT01622361
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT01621451
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Hyperbilirubinemia After Cardiac Surgery
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-06-18
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 1000
- Registration Number
- NCT01617902
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 1Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 272
- Registration Number
- NCT01596517
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Viral Hepatitis B Without Delta-agent
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT01595685
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath